Sellas Life Sciences’ cancer vaccine for acute myeloid leukemia (AML) has passed a phase 3 test with a more than nine-month improvement in overall survival.
The peptide vaccine, called galinpepimut-S (GPS), is Sellas’ lead candidate and targets the WT1 protein present in several tumor types. The phase 3 AML trial met its primary endpoint, with GPS delivering a median overall survival of 24 months versus less than 15 months for best available therapy. GPS also showed a 41% reduction in the risk of death.
The patients in the trial had been in remission with AML either completely or at least twice but still lacked platelet recovery and had undergone multiple salvage therapies or were ineligible for stem cell treatment.
Among 126 patients split between GPS alone and treatments including chemotherapy and AbbVie and Roche’s Venclexta, Sellas last year found it took longer than anticipated to reach the number of patient deaths required for the final analysis. The company had been awaiting 80 patient deaths, which had not occurred until late October this year.
Safety and tolerability were normal, and Sellas plans to begin an accelerated filing with the FDA. The drug, which was licensed from Memorial Sloan Kettering Cancer Center, was granted an orphan designation from the agency in 2023.
“The magnitude of the survival benefit observed with our investigational GPS cancer vaccine immunotherapy represents a defining milestone for Sellas and provides phase 3 validation of our WT1-targeted immunotherapeutic technology,” Sellas CEO Angelos Stergiou, M.D., said in a release. “We believe GPS has the potential to become an important paradigm-shifting option for this high-risk population that desperately needs effective therapies.”
GPS is lined up in a number of clinical programs, including a mid-stage monotherapy trial for malignant pleural mesothelioma, as well as combinations with Bristol Myers Squibb’s Opdivo and Merck’s Keytruda.
Sellas also has a small molecule called SLS009 for AML and will present response and survival outcomes next month at the annual meeting of the American Society of Hematology.